...' proton plans in 41 patients requiring adjuvant comprehensive nodal irradiation for left-sided breast cancer. Cardiotoxicity risk was estimated based on the model by Darby et al. [ 3 ], and risk of recurrence following a compromise in LN coverage was estimated with a linear dose-response model fitted...

... follow-up, 10 (20%) patients developed grade 1 and 2 cardiotoxicities; none developed grade 3 or 4 cardiotoxicities. Furthermore, paclitaxel cardiotoxicity increased among patients with high-risk features including associated diabetes mellitus, hypertension, prior radiotherapy to the chest wall...

... from any ideas, methods, instructions or products referred to in the content or advertisements. Breast cancer Chemotherapy Anthracyclines Epirubicin Cardiotoxicity QT prolongation Anthracyclines play an important role in the neoadjuvant treatment of breast cancer patients [ 1...

... the radiotherapeutic point of view. The current data is briefly described here. A significant cardiotoxicity in modern adjuvant radiotherapy for breast cancer has not been observed with the currently used modern radiation techniques, neither in simple nor in complex planning target volumes. This relates also...

... receptor 2 (HER2)-positive breast cancer (BC). The incidence and long-term impact of trastuzumab-related cardiotoxicity in the community setting is of great clinical importance. Material and Methods: Patients with HER2-positive BC treated with (neo)adjuvant trastuzumab were retrospectively evaluated...

... breast cancer. However, both trastuzumab and anthracycline have cardiotoxicity, and it remains unclear how to use trastuzumab in combination with an anthracycline to curtail their cardiotoxicity. Patients and Methods: From 2010 to 2013, we administered weekly (q1w) paclitaxel (wP) followed by 75 mg/m 2...